{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T07:42:17Z","timestamp":1792914137314,"version":"4.5.0"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Nova Scotia Health Central Zone Pharmacy Department"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to characterize the incidence, grade, onset, duration and management of infusion-related reactions (IRRs) in patients receiving their first cycle of subcutaneous daratumumab and to evaluate the duration of the observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included adult patients diagnosed with MM or AL amyloidosis who received their first cycle of subcutaneous daratumumab in Nova Scotia, Canada, between October 2021 and April 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six IRRs were identified in 5 out of 140 patients (3.6%); 5 of the 6 reactions were categorized as low-grade and one patient developed grade 3 hypoxia which was managed with supplemental oxygen and diphenhydramine. The median time to IRR onset was 49.5\u2005min (range 2\u2013245) and the median time to resolution after intervention was 73.5\u2005min (range 10\u2013101). The IRR rate in patients who received 20\u2005mg of dexamethasone or less was 5.8% versus 0% in patients who received greater than 20\u2005mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world analysis of patients receiving subcutaneous daratumumab for the first time revealed a low rate of IRRs and fewer IRRs in patients who received higher doses of dexamethasone prior to treatment. These findings suggest an important role for dexamethasone in IRR prophylaxis and support a reduction in the duration of the observation period post-subcutaneous daratumumab. Based on these results, the duration of the observation period in Nova Scotia was reduced from 4\u2005h to 1\u2005h, which saves chair time and has implications for cost savings, and the patient experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261500471","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:17:48Z","timestamp":1792588668000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world analysis of infusion-related reactions in patients receiving subcutaneous daratumumab in Nova Scotia, Canada"],"prefix":"10.1177","author":[{"given":"Hyun Woo (Sam)","family":"Jang","sequence":"first","affiliation":[{"name":"Dalhousie University","place":["Canada"]},{"name":"Pharmacy Department, Nova Scotia Health, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Godin","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Nova Scotia Health, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Rolle","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Nova Scotia Health, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"De la Torre","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre and Dalhousie University","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre and Dalhousie University","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-3470","authenticated-orcid":false,"given":"Laura V","family":"Minard","sequence":"additional","affiliation":[{"name":"Dalhousie University","place":["Canada"]},{"name":"Pharmacy Department, Nova Scotia Health, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32128"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02414-6"},{"key":"e_1_3_3_4_2","first-page":"70","article-title":"Darzalex (daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler LA.","year":"2016","unstructured":"Raedler LA. Darzalex (daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. Am Health Drug Benefits 2016; 9: 70\u201373.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631"},{"key":"e_1_3_3_6_2","unstructured":"Janssen Inc. Darzalex\u00ae product monograph. Toronto Ontario. April 2024. Accessed 14 October 2025 from Health Canada Drug Product Database. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=94283"},{"key":"e_1_3_3_7_2","unstructured":"Janssen Inc. Darzalex\u00ae SC product monograph. Toronto Ontario. November 2024. Accessed 14 October 2025 from Health Canada Drug Product Database. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=99226"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000667"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004460"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02985-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16980"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04405-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243790"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000193"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.02.014"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.03.006"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211046911"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00801-1"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00421"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221103551"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01392-1"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-01001-4"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00470"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae158"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241306741"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251400164"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70604"},{"key":"e_1_3_3_30_2","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0. National Cancer Institute 2017."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.05.024"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02810"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261500471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261500471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261500471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T07:26:11Z","timestamp":1792913171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261500471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":31,"alternative-id":["10.1177\/10781552261500471"],"URL":"https:\/\/doi.org\/10.1177\/10781552261500471","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"article-number":"10781552261500471"}}